Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

• Status: Completed
• Trial end date: 2012-02-28
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia. Three doses of dutasteride will be investigated.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Dutasteride; Finasteride

Criteria

Inclusion Criteria:

• Norwood-Hamilton Type III vertex, IV, or V

Exclusion Criteria:

• History or evidence of hair loss other than androgenetic alopecia

• Scarring of the scalp

• Use of dutasteride in previous 18 months

• Use of finasteride within previous 12 months

• Hair transplantation or hair weaving within 6 months

• Use of Minoxidil within previous 6 months

• Use of drugs with anti-androgenetic/androgenetic properties within previous 6 months

• Use of Drugs that cause hypertrichosis or hypotrichosis within previous 6 months

• Light or laser treatment of scalp within previous 3 months

• Cosmetic products aimed at improving or correcting signs of hair loss within previous 2 weeks